ArticleScientific reports2026
Atherogenic index of plasma as a predictor of cardiovascular outcomes in patients with myocardial infarction with nonobstructive coronary arteries.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and Efficacy Assessment of Cannabis Plant Compared to Atorvastatin for Lipid Lowering in Diabetic and Obese Wistar Male Rats.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Atherogenic index of plasma (AIP) has emerged as a novel marker of atherosclerosis and a predictor of outcomes in patients with coronary artery disease. However, the prognostic significance of AIP in a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA) remains unclear. This prospective cohort study included 1179 patients with MINOCA who were stratified by the tertile levels of AIP defined as base 10 logarithm of the ratio of fasting triglyceride to high-density lipoprotein cholesterol. The primary endpoint was major adverse cardiovascular events (MACE) including all-cause death, reinfarction, stroke, revascularization and hospitalization for unstable angina or heart failure. Over the median follow-up of 41.7 months, patients with higher AIP tertiles had more cardiometabolic risk factors and a significantly higher incidence of MACE (9.9%, 14.3%, 18.6%; p = 0.002). Elevated AIP was associated with an increased risk of MACE even after multivariable adjustment [tertile 1 of AIP as reference; tertile 2: hazard ratio (HR) 1.50, 95% confidence interval (CI): 1.03-2.32, p = 0.036; tertile 3: HR 1.78, 95% CI: 1.21-2.63, p = 0.003]. AIP as a continuous marker remained a robust risk factor in all patients and across subgroup analyses. A near-linear relationship was observed between AIP levels and the risk of MACE following MINOCA. Moreover, AIP showed a moderate ability to predict MACE with an area under the curve of 0.67. Higher AIP levels were independently associated with poorer outcomes after MINOCA. These data indicate the role of atherogenic dyslipidemia in MINOCA pathogenesis and support the utility of AIP for risk stratification in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.